IL127919A0 - Stabilized pharmaceutical compositions containing buproprion - Google Patents

Stabilized pharmaceutical compositions containing buproprion

Info

Publication number
IL127919A0
IL127919A0 IL12791999A IL12791999A IL127919A0 IL 127919 A0 IL127919 A0 IL 127919A0 IL 12791999 A IL12791999 A IL 12791999A IL 12791999 A IL12791999 A IL 12791999A IL 127919 A0 IL127919 A0 IL 127919A0
Authority
IL
Israel
Prior art keywords
pct
buproprion
pharmaceutical compositions
compositions containing
stabilized pharmaceutical
Prior art date
Application number
IL12791999A
Other languages
English (en)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10739741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL127919(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IL127919A0 publication Critical patent/IL127919A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12791999A 1993-07-30 1999-01-05 Stabilized pharmaceutical compositions containing buproprion IL127919A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939315856A GB9315856D0 (en) 1993-07-30 1993-07-30 Stabilized pharmaceutical
IL11051399 1999-01-05

Publications (1)

Publication Number Publication Date
IL127919A0 true IL127919A0 (en) 1999-11-30

Family

ID=10739741

Family Applications (3)

Application Number Title Priority Date Filing Date
IL11051394A IL110513A (en) 1993-07-30 1994-07-29 Stabilized pharmaceutical compositions containing bupropion
IL12791994A IL127919A (en) 1993-07-30 1994-07-29 Stabilized pharmaceutical compositions containing bupropion
IL12791999A IL127919A0 (en) 1993-07-30 1999-01-05 Stabilized pharmaceutical compositions containing buproprion

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL11051394A IL110513A (en) 1993-07-30 1994-07-29 Stabilized pharmaceutical compositions containing bupropion
IL12791994A IL127919A (en) 1993-07-30 1994-07-29 Stabilized pharmaceutical compositions containing bupropion

Country Status (22)

Country Link
US (1) US5731000A (xx)
EP (1) EP0711154B1 (xx)
JP (1) JP3721192B2 (xx)
KR (2) KR100350941B1 (xx)
AT (1) ATE232383T1 (xx)
AU (1) AU698883B2 (xx)
CA (1) CA2168364C (xx)
DE (1) DE69432121T2 (xx)
DK (1) DK0711154T3 (xx)
ES (1) ES2189804T3 (xx)
GB (1) GB9315856D0 (xx)
HK (1) HK1004186A1 (xx)
HU (1) HU223528B1 (xx)
IL (3) IL110513A (xx)
MY (1) MY128088A (xx)
NO (1) NO320248B1 (xx)
NZ (1) NZ268951A (xx)
SG (1) SG49790A1 (xx)
SI (1) SI0711154T1 (xx)
TW (1) TW419370B (xx)
WO (1) WO1995003791A1 (xx)
ZA (1) ZA945668B (xx)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652882B1 (en) * 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
US5968553A (en) * 1997-12-30 1999-10-19 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
US6221917B1 (en) 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
WO1999038502A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
JP2002501891A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（＋）−ビュープロピオンの医薬用途
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6153223A (en) * 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
PL345216A1 (en) * 1998-06-29 2001-12-03 Pharmaceuticals Applic Asociat Methods and transdermal compositions for pain relief
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
US6312716B1 (en) * 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US6333332B1 (en) * 2000-08-25 2001-12-25 Impax Laboratories, Inc. Stabilized pharmaceutical compositions containing bupropion hydrochloride
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
KR101072885B1 (ko) * 2002-05-17 2011-10-17 듀크 유니버시티 비만치료방법
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
US20040191298A1 (en) * 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
CA2553207A1 (en) 2004-01-13 2005-08-04 Kishore M. Gadde Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
MXPA06012165A (es) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Chapas para muros, muros de contencion y similares.
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US8586085B2 (en) * 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
KR100670798B1 (ko) 2004-12-17 2007-01-17 한국전자통신연구원 데이터베이스 캐시 시스템
US20060204571A1 (en) * 2005-03-12 2006-09-14 Sun Pharmaceutical Industries Limited Stable compositions of bupropion or its pharmaceutically acceptable salts
RU2408368C2 (ru) * 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
ZA200804086B (en) * 2005-10-14 2009-07-29 Lundbeck & Co As H Stable pharmaceutical formulations containing escitalo-pram and bupropion
WO2007053796A2 (en) * 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
JP5180092B2 (ja) * 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
DK1954241T3 (da) * 2005-11-28 2012-06-18 Orexigen Therapeutics Inc Zonisamid-formulering med vedvarende frigivelse
EP1999303A4 (en) * 2006-02-27 2010-09-08 Univ Leland Stanford Junior METHODS FOR IDENTIFYING RESPONSE INHIBITORS TO DEPLOYED PROTEINS
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
BRPI0712868A2 (pt) 2006-06-13 2013-05-07 Univ Leland Stanford Junior inibidores epàxidos de cisteÍna proteases
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
US8703191B2 (en) 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
KR100843021B1 (ko) * 2006-09-11 2008-07-01 주식회사 드림파마 안정성이 개선된 디에틸프로피온 하이드로클로라이드를포함하는 경구투여용 고형 제제
CN101588795A (zh) 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂
AU2007319472B2 (en) * 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
WO2008124128A2 (en) 2007-04-09 2008-10-16 Sepracor Inc. Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
US9339500B2 (en) * 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
EP3659604A1 (en) * 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
AU2011313853A1 (en) 2010-10-11 2013-05-02 Auckland Uniservices Limited Substituted benzamides and their uses
KR101534606B1 (ko) * 2011-11-08 2015-07-10 알보젠코리아 주식회사 사포그릴레이트의 안정화된 지속 방출 제제
PL2782570T3 (pl) 2011-11-21 2020-04-30 Calithera Biosciences Inc. Heterocykliczne inhibitory glutaminazy
RU2014141510A (ru) 2012-04-12 2016-06-10 Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити Замещенные бензамиды и их применения, перекрестная ссылка на связанные заявки
HUE049859T2 (hu) 2012-06-06 2020-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatnak kitett páciensekben túlsúly és elhízás kezelésére szolgáló eljárásban történõ alkalmazásra
EP2920168B1 (en) 2012-11-16 2021-07-21 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
KR102279618B1 (ko) 2013-03-15 2021-07-20 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 활성 기반 프로브 화합물, 조성물, 및 사용 방법
US11324670B2 (en) * 2013-10-16 2022-05-10 Bilal Walk Cocoa butter powdered moisturizer
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
KR20170012562A (ko) 2014-06-13 2017-02-02 칼리테라 바이오사이언시즈 인코포레이티드 글루타미나제 억제제를 사용하는 병용 요법
EA037738B1 (ru) 2014-08-07 2021-05-17 Калитера Байосайенсиз, Инк. Кристаллические формы ингибиторов глутаминазы
JP6663909B2 (ja) 2014-08-13 2020-03-13 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターモジュレーターとしてのジフルオロピロリジン
US20170333450A1 (en) 2014-10-31 2017-11-23 The Regents Of The University Of California Compositions and methods for treating hiv-associated cognitive dysfunction
KR101612197B1 (ko) * 2014-11-25 2016-04-14 알보젠코리아 주식회사 부프로피온 염산염을 함유하는 안정화된 정제 및 이의 제조방법
CU24509B1 (es) 2015-03-10 2021-05-12 Aurigene Discovery Tech Ltd Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores
WO2016210106A1 (en) 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
SG11201802830QA (en) 2015-10-05 2018-05-30 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors and immuno-oncology agents
MA43131B1 (fr) 2015-10-30 2020-07-29 Calithera Biosciences Inc Compositions et procédés d'inhibition de l'activité de l'arginase
WO2017087517A1 (en) 2015-11-16 2017-05-26 Demeter Therapeutics, Llc Nucleic acid prodrugs
EP3414241B1 (en) 2016-02-12 2022-05-04 Astrazeneca AB Halo-substituted piperidines as orexin receptor modulators
US10793590B2 (en) 2016-06-03 2020-10-06 President And Fellows Of Harvard College Antifungal compounds
WO2018039612A1 (en) 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions and methods for promoting hair growth with mpc1 inhibitors
EP3509583B1 (en) 2016-09-09 2021-06-30 The Regents of the University of California Estrogen receptor ligands, compositions and methods related thereto
WO2018049145A1 (en) 2016-09-09 2018-03-15 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
CA3034652A1 (en) 2016-09-26 2018-03-29 Dana-Farber Cancer Institute, Inc. Chromobox protein inhibitors and uses thereof
US11510931B2 (en) 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
DK3519050T3 (da) 2016-09-28 2023-07-24 Medicon Pharmaceuticals Inc Sammensætninger til behandling af oftalmiske sygdomme
WO2018089490A1 (en) 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
AU2017382405B2 (en) 2016-12-22 2021-12-16 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
EP3510380B1 (en) 2016-12-23 2023-11-08 The Board of Trustees of the Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
EP3570843A1 (en) 2017-01-18 2019-11-27 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
CA3053068A1 (en) 2017-02-24 2018-08-30 Merck Patent Gmbh 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
IL293783B2 (en) 2017-03-31 2024-01-01 Aurigene Oncology Ltd Compounds and preparations for the treatment of hematological disorders
WO2018209288A1 (en) 2017-05-12 2018-11-15 Massachusetts Institute Of Technology Argonaute protein-double stranded rna complexes and uses related thereto
WO2018223032A1 (en) 2017-06-02 2018-12-06 Stealth Biotherapeutics Corp. Crystalline salt forms of sbt-20
AU2018294351B2 (en) 2017-06-30 2022-12-22 The Regents Of The University Of California Compositions and methods for modulating hair growth
US10526334B2 (en) 2017-07-19 2020-01-07 California Institute Of Technology Methods for preparing bis-tetrahydroisoquinoline-containing compounds
EA202090536A1 (ru) 2017-10-11 2020-07-22 Ориджен Дискавери Текнолоджис Лимитед Кристаллические формы 3-замещенного 1,2,4-оксадиазола
PL3704108T3 (pl) 2017-10-31 2024-07-22 Curis, Inc. Inhibitor irak4 w połączeniu z inhibitorem bcl-2 do stosowania w leczeniu nowotworu złośliwego
EA202090746A1 (ru) 2017-11-03 2020-08-17 Ориджен Дискавери Текнолоджис Лимитед Двойные ингибиторы путей tim-3 и pd-1
WO2019087092A1 (en) 2017-11-06 2019-05-09 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
US11479539B2 (en) 2017-12-22 2022-10-25 Medimmune Limited Small molecule modulators of the BTB domain of Keap1
EP3765460A1 (en) 2018-03-14 2021-01-20 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
EP3773614A1 (en) 2018-04-12 2021-02-17 Matrx Therapeutics Corporation Compositions and methods for treating elastic fiber breakdown
WO2019217450A1 (en) 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
EP3813841A4 (en) 2018-06-29 2022-03-09 The Regents Of The University Of California NEW MOLECULAR FORCEPS AGAINST NEUROLOGICAL DISORDERS AND VIRAL INFECTION
JP2021531349A (ja) 2018-07-27 2021-11-18 カリフォルニア インスティチュート オブ テクノロジー Ｃｄｋインヒビター及びその使用
KR20210071974A (ko) 2018-09-05 2021-06-16 더 제너럴 하스피탈 코포레이션 사이토카인 방출 증후군을 치료하는 방법
CN114269345A (zh) 2018-10-26 2022-04-01 科乐斯疗法公司 Alk2抑制剂的晶体形式
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CA3125991A1 (en) 2019-01-25 2020-07-30 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
JP2022523510A (ja) 2019-01-31 2022-04-25 エレクトロフィ，インコーポレイテッド 粒子形成及び形態構造
BR112021017960A2 (pt) 2019-03-14 2021-11-23 Astrazeneca Ab Lanabecestate para perda de peso
WO2020246503A1 (ja) 2019-06-03 2020-12-10 株式会社大分大学先端医学研究所 狂犬病治療のための環状アミド化合物およびその方法
CN110200947A (zh) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 一种安非他酮肠溶缓释微丸胶囊及其制备方法
EP4027978A1 (en) 2019-09-13 2022-07-20 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
KR20220100625A (ko) 2019-11-12 2022-07-15 젠자임 코포레이션 결핍된 cftr 활성에 의해 매개되는 질환 및 병태를 치료하기 위한 6원 헤테로아릴아미노설폰아미드
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
CN114901290B (zh) 2019-12-16 2024-09-03 蔚山科学技术院 抑制血管新生因子的化合物及其用途
US20230113944A1 (en) 2020-01-10 2023-04-13 The Regents Of The University Of California Compositions and methods for the treatment of neurodegenerative diseases
WO2021158959A2 (en) 2020-02-07 2021-08-12 Elektrofi, Inc. Peptide particles and methods of formation
US20230065628A1 (en) 2020-02-19 2023-03-02 Elektrofi, Inc. Droplet Formation and Particle Morphology
AU2021257476A1 (en) 2020-04-17 2022-11-03 Elektrofi, Inc. Methods of forming particles by continuous droplet formation and dehydration
JP7519463B2 (ja) 2020-05-05 2024-07-19 ヌバレント， インク． ヘテロ芳香族大環状エーテル化学療法剤
WO2021263072A1 (en) 2020-06-25 2021-12-30 Dana-Farber Cancer Institute, Inc. Methods of treating disease
AU2021324967A1 (en) 2020-08-10 2023-03-16 Dana-Farber Cancer Institute, Inc. Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
WO2022035806A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
WO2022035805A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
US20230399304A1 (en) 2020-10-23 2023-12-14 Dana-Farber Cancer Institute, Inc. Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer
KR20230113787A (ko) 2020-12-01 2023-08-01 안테씨프 바이오벤쳐스 투 엘엘씨 우울증 환자의 자살 위험 감소를 위한 부프로피온 및덱스트로메토르판
WO2022133237A2 (en) 2020-12-18 2022-06-23 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
JP2024504512A (ja) 2020-12-21 2024-01-31 コーネル・ユニバーシティー ペプチド連結薬物送達系
WO2022150574A1 (en) 2021-01-08 2022-07-14 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
WO2022221227A1 (en) 2021-04-13 2022-10-20 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
CN118201919A (zh) 2021-09-03 2024-06-14 健赞公司 吲哚化合物和使用方法
WO2023034946A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
CA3231813A1 (en) 2021-10-01 2023-04-06 Sibao CHEN Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
CA3231608A1 (en) 2021-10-01 2023-04-06 Amit M. Deshpande Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
WO2023187422A1 (en) 2022-03-31 2023-10-05 Revolo Biotherapeutics Limited Compositions and their use in methods for treating intestinal inflammation
WO2023196910A1 (en) 2022-04-07 2023-10-12 Nuvalent, Inc Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
WO2023196900A1 (en) 2022-04-07 2023-10-12 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2023212721A1 (en) 2022-04-29 2023-11-02 Elektrofi, Inc. Injectable suspensions
WO2023223015A1 (en) 2022-05-16 2023-11-23 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating food allergies
WO2023250157A1 (en) 2022-06-24 2023-12-28 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US20240277849A1 (en) * 2022-06-30 2024-08-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
WO2024013209A1 (en) 2022-07-13 2024-01-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2024036097A1 (en) 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds and isotopologues thereof
WO2024036098A1 (en) 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds
WO2024086634A1 (en) 2022-10-19 2024-04-25 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
BE759838A (fr) * 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US4347257A (en) * 1979-10-09 1982-08-31 Burroughs Wellcome Co. Prolactin suppression in mammals
NZ196048A (en) * 1980-01-21 1984-07-31 Wellcome Found Anti-depressant compositions with reduced induction of drowsiness-benzodiazepine tranquilliser/m-(chloro or fluoro)-t-butylaminopropiophenone
US4347382A (en) * 1980-04-15 1982-08-31 Burroughs Wellcome Co. 3H Labeled compounds
US4347178A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making
US4355179A (en) * 1980-04-14 1982-10-19 Burroughs Wellcome Co. Radioactive nuclide labeled propiophenone compounds
US4356165A (en) * 1980-04-14 1982-10-26 Burroughs Wellcome Co. Bupropion radioimmunoassay, and kit
US4347177A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making them
US4347176A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making same
US4435449A (en) * 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4425363A (en) * 1981-05-14 1984-01-10 Burroughs Wellcome Co. Treatment of tardive dyskinesia in mammals
US4393078A (en) * 1982-03-15 1983-07-12 Burroughs Wellcome Co. Bupropion and ethanol
US4438138A (en) * 1982-12-06 1984-03-20 Burroughs Wellcome Co. Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
GB2134516A (en) * 1983-02-03 1984-08-15 Wellcome Found Biologically active ketone derivative, preparation and use
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4507323A (en) * 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
DE3486409T2 (de) * 1984-08-17 1996-04-25 Wellcome Found Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
JPH06507416A (ja) * 1991-05-07 1994-08-25 ダイナジェン・インコーポレーテッド 禁煙のための調節された持続的放出伝達システム
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer

Also Published As

Publication number Publication date
CA2168364C (en) 2001-09-18
NO320248B1 (no) 2005-11-14
DE69432121D1 (de) 2003-03-20
US5731000A (en) 1998-03-24
WO1995003791A1 (en) 1995-02-09
SG49790A1 (en) 1998-06-15
AU7235294A (en) 1995-02-28
JP3721192B2 (ja) 2005-11-30
ZA945668B (en) 1996-01-29
SI0711154T1 (en) 2003-08-31
NO960373L (no) 1996-01-29
EP0711154B1 (en) 2003-02-12
MY128088A (en) 2007-01-31
EP0711154A1 (en) 1996-05-15
KR100350941B1 (ko) 2002-12-26
NZ268951A (en) 1997-03-24
HK1004186A1 (en) 1998-11-20
HU223528B1 (hu) 2004-08-30
DK0711154T3 (da) 2003-06-10
JPH09506070A (ja) 1997-06-17
IL127919A (en) 2003-03-12
IL110513A (en) 1999-06-20
AU698883B2 (en) 1998-11-12
HU9501879D0 (en) 1995-08-28
DE69432121T2 (de) 2003-10-16
ATE232383T1 (de) 2003-02-15
TW419370B (en) 2001-01-21
KR100350940B1 (ko) 2002-08-30
CA2168364A1 (en) 1995-02-09
HUT73677A (en) 1996-09-30
GB9315856D0 (en) 1993-09-15
ES2189804T3 (es) 2003-07-16
NO960373D0 (no) 1996-01-29
IL110513A0 (en) 1994-10-21

Similar Documents

Publication Publication Date Title
IL127919A0 (en) Stabilized pharmaceutical compositions containing buproprion
CA2303339A1 (en) A pharmaceutical composition for treating dysmenorrhea and premature labor
GR3021551T3 (en) Pharmaceutical composition containing terbinafine as an anti-mycotic agent
GEP20032999B (en) 1-Heterocycle Substituted Diarylamines
PL314188A1 (en) Novel derivatives of benzoguanidine, method of obtaining them and their application in pharmaceutical compositions
CA2316981A1 (en) Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
IL110159A0 (en) Diaryl compounds, their preparation and pharmaceutical compositions containing them
CY2280B1 (en) Pharmaceutical composition for transdermic delivery
IL112637A0 (en) A pharmaceutical composition containing oxybutynin and methods for the preparation thereof
HU9900879D0 (en) Reverse fluorocarbon emulsion compositions for drug delivery
HK1002017A1 (en) Lyospheres comprising gonadotropin
GR3025014T3 (en) A pharmaceutical composition for the intranasal administration of hydroxocobalamin
CA2108455A1 (en) Pharmaceutical compositions against gastric disorders
TW327601B (en) Compositions for use in inhibiting uterine fibrosis
CA2316985A1 (en) Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
UA39101C2 (uk) ПОХІДНІ 11<font face="Symbol">b</font>-БЕНЗАЛЬДОКСИМ-ЕСТРА-4,9-ДІЄНУ, СПОСІБ ЇХ ОДЕРЖАННЯ І ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ З АНТИПРОГЕСТИНОВОЮ АКТИВНІСТЮ
HUP9801880A3 (en) Novel cryptophycins, their use and pharmaceutical compositions containing them
GB9424766D0 (en) Pharmaceutical composition
EP0683668A4 (en) PREPARATIONS AND METHODS FOR TRANSDERMAL DRUG ADMINISTRATION.
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
NZ241234A (en) Amino polyhydroxy cyclohexane derivatives and medicaments
ZA943157B (en) Substituted benzodioxins, a process for their prepration and pharmaceutical compositions containing them.
IL110833A0 (en) Naphthoxazines, their preparation and pharmaceutical compositions containing them
GR3034551T3 (en) Cyclic nitrones, their preparation and pharmaceutical compositions containing them.
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis